Gilead Sciences’ lenacapavir is already expected to have a significant advantage among injected HIV drugs thanks to its twice-yearly injection schedule when the company launches it for pre-exposure prophylaxis (PrEP), but now it has Phase I data showing PrEP efficacy as a single annual injection. Gilead presented the data on 11 March at the Conference on Retroviruses and Opportunistic Infections (CROI).
Key Takeaways
- As it awaits the launch of twice-yearly lenacapavir for PrEP, Gilead stirred the competitive pot further with early data indicating the potential for once-yearly administration.
The Foster City, CA-based drug maker further presented on 12 March Phase II data showing the efficacy of lenacapavir combined with the broadly neutralizing antibodies (bNAbs) teropavimab and zinlirvimab as...